These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16922792)

  • 1. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
    Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
    Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
    Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
    J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
    Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
    Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation.
    Singhal S; Ellis RW; Jones SG; Miller SJ; Fisher NC; Hastings JG; Mutimer DJ
    Liver Transpl; 2000 Sep; 6(5):588-95. PubMed ID: 10980058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
    Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
    Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).
    Ito JI; Chandrasekar PH; Hooshmand-Rad R
    Bone Marrow Transplant; 2005 Nov; 36(10):873-7. PubMed ID: 16113663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
    Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
    Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
    Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation.
    Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J
    Pediatr Transplant; 1997 Nov; 1(2):124-9. PubMed ID: 10084772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders.
    Hovi L; Saxen H; Saarinen-Pihkala UM; Vettenranta K; Meri T; Richardson M
    Pediatr Blood Cancer; 2007 Jan; 48(1):28-34. PubMed ID: 16395687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases.
    Martino R; Nomdedéu J; Altés A; Sureda A; Brunet S; Martínez C; Domingo-Albós A
    Bone Marrow Transplant; 1994 Mar; 13(3):265-9. PubMed ID: 8199569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
    J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy.
    Grigull L; Kuehlke O; Beilken A; Sander A; Linderkamp C; Schmid H; Seidemann K; Sykora KW; Schuster FR; Welte K
    Pediatr Transplant; 2007 May; 11(3):261-6. PubMed ID: 17430480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis.
    Jantunen E; Nihtinen A; Volin L; Juvonen E; Parkkali T; Ruutu T; Anttila VJ
    Bone Marrow Transplant; 2004 Nov; 34(10):891-5. PubMed ID: 15517009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.